- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02838628
Activity & Safety Study of KX2-391 Ointment in Participants With Actinic Keratosis on the Face or Scalp
A Phase 2a, Open-Label, Multicenter, Activity and Safety Study of KX2-391 Ointment 1% in Subjects With Actinic Keratosis on the Face or Scalp
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study was an open-label, multicenter, activity, safety, tolerability, and PK study of KX2-391 Ointment administered topically to the face or scalp of participants with AK.
The study consists of Screening, Treatment, and Follow-up Periods. Eligible participants were received 3 or 5 consecutive days of topical treatment, applied at the study site. Blood samples for PK analysis were collected. Activity (lesion counts) and safety evaluations were performed.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Fremont, California, United States, 94538
- Center for Dermatology Clinical Research
-
La Mesa, California, United States, 91942
- eStudy Site
-
Palm Springs, California, United States, 92262
- Palmtree Clinical Research, Inc.
-
-
Colorado
-
Denver, Colorado, United States, 80220
- Horizons Clinical Research Center
-
-
Florida
-
Coral Gables, Florida, United States, 33134
- Clinical Research of South Florida
-
Miami, Florida, United States, 33144
- International Dermatology Research
-
Orlando, Florida, United States, 32806
- Compass Research
-
Tampa, Florida, United States, 33624
- Forward Clinical Trials, Inc.
-
West Palm Beach, Florida, United States, 33409
- Palm Beach Research Center
-
-
Minnesota
-
Fridley, Minnesota, United States, 55432
- Minnesota Clinical Study Center
-
-
South Carolina
-
Charleston, South Carolina, United States, 29414
- Dermatology and Laser Center of Charleston
-
-
Tennessee
-
Murfreesboro, Tennessee, United States, 37130
- Institute of Clinical Research - Tennessee, LLC
-
-
Texas
-
College Station, Texas, United States, 77845
- J&S Studies, Inc.
-
Houston, Texas, United States, 77056
- The Center for Skin Research
-
San Antonio, Texas, United States, 78229
- Clinical Trials of Texas, Inc.
-
San Antonio, Texas, United States, 78229
- Dermatology Clinical Research Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Males and females ≥18 years old
- Clinical diagnosis of stable, clinically typical actinic keratosis
- A define treatment area on the face or scalp
- Females must be postmenopausal, surgically sterile or otherwise incapable of pregnancy for at least 1 year; or must be using highly effective contraception for at least 90 days prior to treatment with KX2-391 Ointment
- Males who have not had a vasectomy must agree to use barrier contraception
- Participants who in the judgment of the Investigator, are in good general health
- Willing to avoid excessive sun exposure
- Able to comprehend and are willing to sign an informed consent form (ICF)
Exclusion Criteria:
- Clinically atypical and/or rapidly changing AK lesions on the treatment area
- Malignancy within 5 years prior to Screening except basal or squamous cell carcinoma not on the treatment area that were treated with curative intent and are without recurrence
- Used any of retinoids at the most 90 days before Visit 1 glucocorticosteroids and methotrexate or other anti-metabolites within, at the most 28 days, before Visit 1
- Used any topical therapies, treatments, or surgical or destructive modalities on the treatment area within, at the most 90 days, before Visit 1
- Currently, or has experienced cutaneous malignancy, sunburn or body art on the treatment area within, at the most 180 days, before Visit 1
- A history of sensitivity and/or allergy to any of the ingredients in the study medication
- A skin disease or condition that, in the opinion of the Investigator, might interfere with the study conduct or evaluations, or which exposes the participant to an unacceptable risk by study participation
- Other significant uncontrolled or unstable medical diseases or conditions that, in the opinion of the Investigator, would expose the participant to unacceptable risk by study participation
- Females who are pregnant or nursing
- Participated in an investigational drug trial during which an investigational study medication was administered within 14 days or 5 half-lives of the investigational product, whichever is longer, before dosing.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: KX2-391 50 mg (Days 1 to 5)
Participants were applied 50 milligrams (mg) of KX2-391 Ointment 1% topically on face or scalp in 25 centimeter square (cm^2) treatment area, once daily for 5 consecutive days.
|
Dose: 50 mg; Route of administration: Topical
|
EXPERIMENTAL: KX2-391 50 mg (Days 1 to 3)
Participants were applied 50 mg of KX2-391 Ointment 1% topically on face or scalp in 25 cm^2 treatment area, once daily for 3 consecutive days.
|
Dose: 50 mg; Route of administration: Topical
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Complete Response of Actinic Keratosis
Time Frame: Day 57
|
Complete response rate was defined as the percentage of participants achieving 100% clearance in the treatment area on the face or scalp at Day 57.
|
Day 57
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Partial Response of Actinic Keratosis
Time Frame: Day 57
|
Partial response rate was defined as the percentage of participants achieving more than or equal to 75% clearance in the treatment area on the face or scalp at Day 57.
|
Day 57
|
Overall Change From Baseline in Actinic Keratosis Lesion Counts at Day 8, 15, 29 and 57
Time Frame: Baseline, Days 8, 15, 29 and 57
|
Overall changes from baseline in actinic keratosis lesion counts has been reported.
|
Baseline, Days 8, 15, 29 and 57
|
Number of Participants With Any Treatment-emergent Adverse Events (TEAEs)
Time Frame: Baseline up to Day 57 (Treatment and follow-up period)
|
An adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical investigation participant administered an investigational Product (IP).
An AE did not necessarily have a causal relationship with the medicinal product.
An SAE was defined as any untoward medical occurrence that at any dose, resulted in death, was life-threatening (i.e, the participant was at immediate risk of death from the AE as it occurred; this did not include an event that, had it occurred in a more severe form or was allowed to continue, might have caused death), required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug).
TEAEs were defined as either those AEs with an onset after dosing or those pre-existing conditions that worsened after dosing.
TEAEs included both serious and non-serious TEAEs.
|
Baseline up to Day 57 (Treatment and follow-up period)
|
Number of Participants With Any Treatment-emergent Adverse Events During Recurrence Follow-up Period
Time Frame: From Day 57 up to 12-months post-Day 57 (Recurrence follow-up period)
|
An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant administered an IP.
An AE did not necessarily have a causal relationship with the medicinal product.
An SAE was defined as any untoward medical occurrence that at any dose, resulted in death, was life-threatening (i.e, the participant was at immediate risk of death from the AE as it occurred; this did not include an event that, had it occurred in a more severe form or was allowed to continue, might have caused death), required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug).
TEAEs were defined as either those AEs with an onset after dosing or those pre-existing conditions that worsened after dosing.
TEAEs included both serious and non-serious TEAEs.
|
From Day 57 up to 12-months post-Day 57 (Recurrence follow-up period)
|
Number of Participants With Maximal Post Baseline Local Skin Reactions (LSRs)
Time Frame: Day 57
|
Maximal post baseline LSR was defined as the highest grade of any LSR reported at any post baseline visits for a participant.
Local skin reactions assessment included signs of erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration on the treatment area.
These signs were assessed using a 5-point grading scale ranging from 0 (not present) to 4 (worst), where (grade 0 = absent, grade 1 = slight, grade 2 = moderate, grade 3 = severe, grade 4 = very severe).
|
Day 57
|
Number of Participants With Clinically Significant Abnormalities in Laboratory
Time Frame: Baseline to Day 57
|
Laboratory parameters included hematology, blood chemistry and urinalysis.
Clinical significance was determined by the investigator.
|
Baseline to Day 57
|
Number of Participants With Clinically Significant Abnormalities in Vital Signs
Time Frame: Baseline up to Day 57
|
Vital signs included measurement of pulse rate, systolic and diastolic blood pressure, respiratory rate, and body temperature.
Clinical significance was determined by the investigator.
|
Baseline up to Day 57
|
Number of Participants With Clinically Significant Abnormalities in Electrocardiograms (ECGs)
Time Frame: Baseline up to Day 57
|
ECG parameters included heart rhythm, heart rate, QRS intervals, QT intervals, RR intervals and corrected QT (QTc) intervals.
Clinical significance was determined by the investigator.
|
Baseline up to Day 57
|
Number of Participants With Clinically Significant Abnormalities in Physical Examination (PE)
Time Frame: Baseline up to Day 57
|
A physical examination included weight and height measurements was performed.
Clinical significance was determined by the investigator.
|
Baseline up to Day 57
|
Maximum Observed Plasma Concentration (Cmax) of KX2-391 of KX2-391
Time Frame: Pre-dose, 0.5, 1 and 4 hours post-dose on Days 1, 3 (Cohort 2) and 5 (Cohort 1)
|
Cmax was defined as the maximum observed plasma concentration obtained directly from the concentration versus time curve.
|
Pre-dose, 0.5, 1 and 4 hours post-dose on Days 1, 3 (Cohort 2) and 5 (Cohort 1)
|
Area Under the Plasma Concentration Time Curve From Time 0 to the Last Sampling Time (AUCt) of KX2-391
Time Frame: Pre-dose, 0.5, 1 and 4 hours post-dose on Days 1, 3 (Cohort 2) and 5 (Cohort 1)
|
Area under the plasma concentration versus time curve from time zero to the last sampling time (t) at which the concentration is at or above the LLOQ.
AUC(0-t) was calculated according to the mixed log-linear trapezoidal rule.
|
Pre-dose, 0.5, 1 and 4 hours post-dose on Days 1, 3 (Cohort 2) and 5 (Cohort 1)
|
Minimum Observed Plasma Concentration (Cmin) of KX2-391
Time Frame: Pre-dose, 0.5, 1 and 4 hours post-dose on Days 1, 3 (Cohort 2) and 5 (Cohort 1)
|
Cmin was defined as minimum observed plasma concentration obtained directly from the concentration versus time curve.
|
Pre-dose, 0.5, 1 and 4 hours post-dose on Days 1, 3 (Cohort 2) and 5 (Cohort 1)
|
Accumulation Ratio (R)
Time Frame: Pre-dose, 0.5, 1 and 4 hours post-dose on Days 1, 3 (Cohort 2) and 5 (Cohort 1)
|
Ratio calculated from AUC and Cmax found on the last day of treatment and Day 1.
|
Pre-dose, 0.5, 1 and 4 hours post-dose on Days 1, 3 (Cohort 2) and 5 (Cohort 1)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Jane Fang, MD, Kinex Pharmaceuticals Inc.
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KX01-AK-002
- U1111-1173-5677 (OTHER: UTN)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Actinic Keratosis
-
Dolorgiet GmbH & Co. KGd.s.h. statistical services GmbH; CenTrial GmbHCompletedActinic Keratosis Olsen Grade I/IIGermany
-
Cosmetique Active InternationalNot yet recruiting
-
Centre Dermatologique du RoyCompleted
-
Encube Ethicals Pvt. Ltd.CBCC Global ResearchCompleted
-
University of California, DavisActive, not recruiting
-
Northwestern UniversityWithdrawn
-
Tulane UniversityMayne Pharma International Pty LtdTerminatedActinic KeratosesUnited States
-
Medical University of ViennaTerminatedActinic KeratosesAustria
-
University Hospital RegensburgGerman Research FoundationCompleted
-
St Vincent's University Hospital, IrelandCompleted
Clinical Trials on 50 mg of KX2-391 Ointment 1%
-
Almirall, S.A.Athenex, Inc.CompletedActinic KeratosesUnited States
-
Almirall, S.A.Athenex, Inc.CompletedActinic KeratosisUnited States
-
Athenex, Inc.TKL Research, Inc.Completed
-
Athenex, Inc.CompletedActinic KeratosisUnited States
-
Athenex, Inc.Completed
-
Kinex Pharmaceuticals Inc.CompletedAcute Myelogenous LeukemiaUnited States
-
Athenex, Inc.CompletedBone-Metastatic, Castration-Resistant Prostate CancerUnited States
-
LEO PharmaCompleted
-
Roswell Park Cancer InstituteCompletedLymphoma | Small Intestine Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Lymphoproliferative DisorderUnited States
-
Hanmi Pharmaceutical Company LimitedUnknownBreast Cancer | Gastric Cancer | Unspecified Adult Solid Tumor, Protocol SpecificKorea, Republic of